Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34099
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18034/20233 (89%)
造访人次 : 24008209      在线人数 : 488
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34099


    標題: Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma IdentifiesRASandPIK3CAMutations as Negative Survival Predictors
    作者: Lai, Wei-An
    Liu, Chih-Yi
    Lin, Shih-Yao
    Chen, Chien-Chin
    Hang, Jen-Fan
    貢獻者: Taipei Vet Gen Hosp, Dept Pathol & Lab Med
    Sijhih Cathay Gen Hosp, Div Pathol
    Far Eastern Mem Hosp, Dept Pathol
    Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Pathol
    Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
    Natl Yang Ming Univ, Sch Med
    關鍵字: anaplastic thyroid carcinoma
    RAS
    BRAF(V600E)
    PIK3CA
    TERTpromoter
    TP53
    日期: 2020
    上傳時間: 2022-11-18 11:23:52 (UTC+8)
    出版者: Mdpi
    摘要: Anaplastic thyroid carcinoma (ATC) is rare but highly aggressive. We investigated the association of selected driver mutations, includingBRAF,RAS,PIK3CA,TERTpromoter,TP53,POLE, and mismatch repair deficiency (MMR-D) with the clinicopathological features of ATC to identify prognostic and predictive biomarkers. Thirty-nine retrospective cases from pathology archives were enrolled for clinicopathology analysis and immunohistochemistry, and 27 cases had sufficient specimens for further molecular testing using targeted next-generation sequencing and mass spectrometry.BRAF(V600E)andRASmutations were identified in 25.9% and 40.7% of ATC, respectively.BRAF(V600E)mutation was significantly associated with coexisting papillary thyroid carcinoma (p= 0.009) andRASmutations with female gender (p= 0.012). In univariant analysis, the non-BRAF/RAStumors were significantly associated with the presence of a sarcomatoid pattern (p= 0.045).PIK3CA,TERTpromoter, andTP53mutations were identified in 14.8%, 81.5%, and 70.4% of cases, respectively. No MMR-D orPOLEmutations were detected. In survival analyses,RASandPIK3CAmutations were significantly associated with inferior outcomes (p= 0.03 andp= 0.006, respectively). In conclusion, driver mutations in ATC are associated with distinct clinicopathological features.RASandPIK3CAmutations were negative predictors for patient survival. Emerging therapeutic agents targeting BRAF, RAS, and PI3 kinase may benefit a substantial proportion of ATC patients.
    關聯: Cancers, v.12, n.7, pp.13
    显示于类别:[化妝品應用與管理系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML330检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈